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Abstract:  Biologicals  revolutionized  the  treatment  of  Rheumatoid  Arthritis  (RA).  The  targeted  suppression  of  key 
inflammatory pathways involved in joint inflammation and destruction allows better disease control, which, however, 
comes at the price of an elevated infection risk due to relative immunosuppression. The disease-related infection risk and 
the  infection  risk  associated  with  the  use  of  TNF-α  inhibitors  (infliximab,  adalimumab,  etanercept,  golimumab  and 
certolizumab pegol), rituximab, abatacept and tocilizumab are discussed. Risk factors clinicians need to take into account 
when selecting the most appropriate biologic therapy for RA patients, as well as precautions and screening concerning a 
number  of  specific  infections,  such  as  tuberculosis,  intracellular  bacterial  infections,  reactivation  of  chronic  viral 
infections and HIV are reviewed. 
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INTRODUCTION 
  The introduction of biological therapies targeting specific 
inflammatory  mediators  revolutionized  the  treatment  of 
rheumatoid arthritis (RA). Targeting key components of the 
immune  system  allows  efficient  suppression  of  the  patho-
logic inflammation cascade that gives rise to RA symptoms 
and  subsequent  joint  destruction.  As  flip  side  of  the  coin, 
treatment  with  biologicals  leaves  the  patient  more  suscep-
tible to  infection by inducing a certain extent of immuno-
suppression.  
  The expanding compendium of targeted therapies for RA 
includes  inhibitors  of  TNF-α  (infliximab,  adalimumab, 
etanercept and the newer antibodies golimumab and certoli-
zumab  pegol),  rituximab  which  targets  the  B-cell  specific 
CD 20 antigen, the T cell costimulation inhibitor abatacept 
and the IL-6 receptor inhibitor tocilizumab. Although much 
remains to be discovered about the precise mechanisms of 
increased infection risk under biologic therapy, it is clear that 
clinical  differences  with  respect  to  type  and  frequency  of 
infectious  complications  exist  between  the  different 
compounds. 
  This  article aims  to summarize  literature data on  com-
pound-related and disease-related infection risk factors that 
clinicians need to take into account when selecting the most 
appropriate biologic therapy for their RA patients. The risk 
of serious infections associated with different biologicals is 
discussed, followed by risks and precautions needed under 
biological therapy with respect to a number of specific infec-
tions, such as tuberculosis, intracellular bacterial infections, 
reactivation of chronic viral infections and HIV. 
DISEASE-RELATED RISK OF INFECTION 
  RA is known to be associated with an increased risk of 
infection  [1,2],  although  it  is  difficult  to  distinguish  the  
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infection  risk  associated  with  the  disease  per  se  from  the 
therapy-associated infection risk. Older studies suggest that 
RA intrinsically entails an elevated susceptibility to infection 
[3], probably through RA-associated changes in the cellular 
immune response [2]. A large population-based retrospective 
study comparing RA patients with matched controls reported 
a nearly doubled incidence of documented infections in RA 
patients [1]. RA severity indices, such as presence of rheu-
matoid  factor,  increased  sedimentation  rate  and  extra-
articular  involvement  are  predictors  of  serious  infection 
episodes  in  RA,  in  addition  to  corticosteroid  use  and  the 
presence  of  comorbidities [4].  Infection  is  also  partly 
responsible for the excess mortality rate in RA patients, with 
infection-related standardised mortality rates in RA patients 
ranging from 4.2 to 14.9 [5].  
THERAPY-RELATED RISK OF INFECTION 
General Appraisal of Serious Infection Risk 
  The infection risk associated with RA treatment should 
always  be  evaluated  against  the  background  of  the 
intrinsically  increased  baseline  risk  of  infection  in  RA 
patients. 
  Corticosteroids,  some  disease-modifying  antirheumatic 
drugs (DMARDs) and targeted biologic therapies all have a 
negative impact on the capacity of RA patients to mount an 
adequate immune response and therefore superimpose addi-
tional  infection  risk  to  the  intrinsically  increased  infection 
susceptibility of this patient population.  
  Corticosteroids are well-known to increase infection risk 
by inducing immunosuppression. The degree to which they 
suppress  immune  competence  increases  with  the  dose  and 
duration  of  treatment.  Treatment  for  longer  than  2  weeks 
with over 20 mg/day of prednisolone or equivalent is com-
monly considered to  induce clinically significant  immuno-
suppression [6], whereas a meta-analysis showed that cumu-
lative doses below 500 mg or mean daily doses below 10 mg 
do not increase the risk of infectious complications and can 
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  Corticosteroids  and  combination  therapy  of  corticoste-
roids and conventional DMARDs were shown to increase the 
risk of serious infections in RA patients, but non-biological 
DMARD therapy without corticosteroids was not associated 
with  increased  incidence  of  infection [4,8],  although  some 
DMARDS (methotrexate, azathioprine,  leflunomide, cyclo-
phosphamide,  cyclosporine)  have  well-known  negative 
effects on the immune system. Hydroxychloroquine, sulfa-
salazine,  and  gold  salts  do  not  have  immunosuppressive 
effects. 
  Biological therapies specifically inhibiting targeted mole-
cules of the immune system allow far better disease control, 
at the expense of an increased risk of infections (reviewed in 
[9]). 
  Most  of  the  available  data  on  the  infection  risk  of 
targeted therapies concern inhibitors of tumor necrosis factor 
alpha (TNF-α), which have been in clinical use the longest, 
while  information  on  the  newer  biologicals  is  much  more 
limited. Infectious complications of biological therapy inc-
lude bacterial infections, such as tuberculosis, Streptococcus 
pneumoniae  and  Listeria  monocytogenes  and  potential 
reactivation  of  viral  infections  such  as  hepatitis  B  or  C, 
herpes and varicella zoster. 
TNF Inhibitors 
  TNF-α  is  a  cytokine  secreted  by  macrophages  in 
response to inflammatory stimuli and is involved in immune 
regulation and inflammation as well as in sepsis, apoptotic 
cell death and cancer. TNF inhibitors were the first class of 
biological agents on the market for the treatment of RA, with 
the first agent etanercept introduced in 1998, so we can now 
look  back  on  a  decade  of  clinical  experience  with  these 
products. Most of the data available concern the first three 
products of this therapeutic class: etanercept, a recombinant 
soluble decoy TNF-receptor; infliximab, a chimeric mono-
clonal anti-TNF antibody; and adalimumab, a fully human 
anti-TNF monoclonal antibody. Studies directly comparing 
the  different  TNF-inhibitors  are  lacking,  but  a  recent  net-
work meta-analysis covering Cochrane reviews on different 
biologicals for RA found a reduced therapy withdrawal rate 
for  adverse  events  under  etanercept  as  compared  with 
infliximab and adalimumab [10]. 
  Although the incidence of infections and serious infec-
tions (defined as life-threatening, requiring hospitalization or 
intravenous antibiotics) in the randomized controlled regis-
tration trials of the first 3 TNF inhibitors etanercept, infli-
ximab  and  adalimumab  mostly  did  not  report  significant 
increases in infection risk with these products in comparison 
with controls [9], epidemiological studies as well as registry 
data  have  revealed  increased  incidences  of  infection  with 
these compounds (reviewed in [9]).  
  A  meta-analysis  of  serious  infections  in  9  randomized 
controlled trials with the anti-TNF antibodies infliximab and 
adalimumab found an odds ratio of serious infections of 2.01 
(95% CI 1.31-3.09) for patients treated with anti-TNF anti-
bodies for at least 12 weeks, in comparison with a control 
population treated with placebo or placebo in combination 
with  DMARDs  [11].  These  findings  contrast  with  a  more 
recent and broader (including etanercept)  meta-analysis by  
 
Leombruno et al., who report only non-significant increases 
in serious adverse event and infection rates under anti-TNF 
therapy  [12].  These  discrepancies  may  be  explained  by 
different study inclusion criteria, but also by the inclusion of 
more  recent  trials,  where  increased  awareness  of  possible 
infectious complications with anti-TNF therapy led to more 
stringent patient screening and selection. 
  In the German RABBIT registry study the relative risks 
for serious infection was 2.82 (95% CI 1.4–5.9) in etaner-
cept-treated patients (corresponding to 15.73 [95% CI 12.6–
19.7] episodes/100 patient-years) and 2.70 (95% CI 1.3–5.9) 
under infliximab treatment (corresponding to 20.59 [95% CI 
16.2–26.2]  episodes/100  patient-years)  in  comparison  with 
patients  treated  with  conventional  DMARDs,  where  the 
incidence rate of serious infections was 5.08 (95% CI 3.5–
7.3)  per  100  patient-years  [13].  In  the  British  Society  for 
Rheumatology Biologics Register, overall serious infection 
rates  during  anti-TNF  therapy  compared  with  DMARD 
treatment were not increased (IRR 1.03, 95% CI 0.68–1.57), 
but in contrast anti-TNF therapy increased the rate of serious 
skin and soft tissue infections (IRR of 4.28, 95% CI 1.06–
17.17)  [14].  A  Swedish  observational  study  reported  an 
increased  relative  risk  for  hospitalisation  due  to  infection 
during the first year of anti-TNF treatment, which subsided 
with increasing duration of treatment [15].  
  A systematic retrospective analysis in a tertiary clinical 
center revealed an increased incidence of serious infections 
during the first course of anti TNF-therapy (10.5 +/- 86.9 per 
100  patient-years,  in  comparison  with  3.4  +/-  38.7  before 
TNF-therapy), with a number needed to harm of 14 [16]. A 
recent  Italian  registry  study  reported  an  incidence  rate  of 
3.59 serious infections per 100 patient-years (95% CI 2.77-
4.41)  in  the  first  36  months  of  anti-TNF  therapy,  without 
significant  differences  in  incidence  and  type  of  infection 
between the different anti-TNF agents [17]. 
  A  recent  study  using  data  from  the  North  American 
CORRONA registry indicates that MTX and TNF inhibitor 
therapy and the combination of both are all associated with a 
comparable increase in the incidence of overall infections as 
well as opportunistic infections [18].  
  Data on the infectious complication risk with the newer 
TNF-inhibitors golimumab and  certolizumab are still limi-
ted. Golimumab is a fully human anti-TNF monoclonal anti-
body, whereas certolizumab pegol consists of a humanized 
Fab-fragment  fused  to  polyethylene  glycol  (PEG)  moiety. 
Replacement  of  the  Fc-fragment  by  PEG  may  avoid  Fc-
mediated  side  effects  such  as  complement  activation,  may 
contribute to its preferential distribution to inflamed tissues 
and increases the half-life of certolizumab pegol to 14 days. 
  RCTs with golimumab (reviewed in [19]) report serious 
infection rates of 0.98 to 2.44 percent over 24 weeks [20-22], 
with  one  study  observing  serious  infections  in  2.19%  of 
patients  over  a  one-year  period  [23].  These  figures  are  in 
range with what has been reported for other anti-TNF agents. 
In the FAST4WARD study, monotherapy with certolizumab 
pegol  yielded  a  serious  infection  incidence  rate  of  1.8%, 
whereas  combination  of  certolizumab  with  MTX  induced 
serious  infections  in  2.85  and  4.99%  of  treated  patients 
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Rituximab 
  Rituximab  is  a  genetically  engineered  chimeric  mono-
clonal  antibody  that  targets  CD20-positive  B  cells.  By 
binding to CD20, rituximab depletes subpopulations of peri-
pheral B cells through different mechanisms, including cell-
mediated and  complement-dependent cytotoxicity and pro-
motion of apoptosis. B cells can contribute to the initiation 
and maintenance of the inflammatory cascade in RA by act-
ing  on  antigen  presentation  by  T  cells  and  through  pro-
duction of pro-inflammatory cytokines and auto-antibodies. 
  The  incidence  of  serious  infections  under  rituximab 
treatment appears to be rather limited: 1.27 to 2.27% over 24 
weeks [26,27], 4.96% over 48 weeks [28]. A recent meta-
analysis  reported  that  the  overall  pooled  odds  ratio  for 
serious  infection  under  rituximab  treatment  was  not  signi-
ficantly  increased  (OR  1.45,  95%  CI  0.56-3.73)  [29].  All 
serious  infections  occurred  in  patients  treated  with  the 
highest (2 times 1000 mg) dose of rituximab [29]. Although 
the overall increase in infection risk under rituximab seems 
to be limited, rituximab treatment has been associated with 
rare  cases  of  progressive  multifocal  leukoencephalopathy 
(PML) (read further). 
Abatacept 
  The T cell costimulation modulator abatacept is a fully 
human  soluble  fusion  protein  that  consists  of  the  extra-
cellular domain of human CTLA-4 linked to the modified Fc 
portion  of  human  IgG1.  Upon  antigen  recognition  T  cells 
require  a  costimulatory  signal  for  full  activation.  Like  the 
natural  CTLA4  molecule,  abatacept  interferes  with  the 
CD80/CD86 binding to T cell CD28 with higher avidity than 
CD28. 
  The limited data available on abatacept suggest that the 
risk of serious infections with these products may be more 
limited than that of the TNF inhibitors. Abatacept phase III 
RCT’s reported serious infection incidences of 2.33% [30] 
and 2.39% [31] over 26 weeks, and 2.54% [32] to 3.13% 
[33] over one year. A five year extension of a 1 year double 
blind RCT reported 3.0 serious infections per 100 patient-
years over the whole study period, versus 2.1/100 patient-
years in the first year of the study [34]. In the ATTEST trial 
which compared  the  efficacy  and safety of  infliximab and 
abatacept plus MTX in patients with insufficient response to 
MTX alone, considerably lower rates of  serious  infections 
were observed under abatacept treatment (1.9 versus 8.5%) 
[35]  A  recent  meta-analysis  by  Salliot  et  al.  found  that 
abatacept  did  not  significantly  increase  the  risk  of  serious 
infections in RA patients [29]. 
  The  incidence  of  serious  infection  episodes  does  not 
increase with prolonged abatacept treatment, as evidenced by 
the open label extension studies of the AIM trial, reporting 
4.3 [36] and 3.0 [34] serious infections per 100 patient-years 
after 2 and 5 years of treatment, respectively, in comparison 
with 4.2 serious infections per 100 patient-years observed in 
the 1 year double blind phase of the study [37,38]. 
  Combination of  abatacept with etanercept yielded  little 
clinical  benefit,  but  did  increase  the  incidence  of  serious 
infections (3.5% in the combination group versus 0% in the 
etanercept group) [39]. This study confirmed earlier findings 
that abatacept in combination with another biological agent 
increased the incidence of serious adverse events, including 
serious infections [33]. 
Tocilizumab 
  Tocilizumab is a humanised monoclonal antibody target-
ing the interleukin-6 receptor, which can be found both on 
cell surfaces and in the circulation. Tocilizumab blocks the 
downstream  effects  of  IL-6,  a  cytokine  with  pleiotropic 
effects that contributes to the inflammation cascade in RA, 
by  affecting  the  function  of  neutrophils,  T  cells,  B  cells, 
monocytes,  and  osteoclasts.  Additionally,  IL-6  is  a  potent 
inducer of the hepatic acute phase response.  
  The  risk  of  serious  infections  under  tocilizumab 
treatment  reported  in  RCTs  is  relatively  low,  with  figures 
reported  ranging  from  2.29  to  9.98  per  100  patient-years 
[40]. However, a number of these studies excluded patients 
with a history of  infections or  increased infection risk, so 
further evidence from clinical practice or registry studies is 
needed  in  order  to  assess  the  real-life  infection  risk 
associated with tocilizumab. 
SPECIFIC  INFECTIONS  UNDER  BIOLOGICAL 
THERAPY 
  The  most  common  sites  of  infections  associated  with 
biological therapy are respiratory tract infections - including 
pneumonia - septic arthritis, skin and soft tissue infections, 
and urinary tract infections [9]. As TNF plays an important 
role  in  the  host  defense  mechanism  against  intracellular 
pathogens  [41,42],  anti-TNF  therapy  is  associated  with 
increased  risk  of  infection  with  intracellular  micro-organi-
sms,  such  as  Mycobacterium  tuberculosis,  Listeria  mono-
cytogenes and Legionella pneumophila.  
Intracellular Bacterial Infections 
  Biological  therapies  for  RA  are  associated  with  an 
increased risk of tuberculosis, mainly by reactivation of a 
latent Mycobacterium tuberculosis infection. The impact of 
biological therapies on tuberculosis risk must, however, be 
evaluated against the background of increased incidence of 
tuberculosis (TB) due to RA itself and regional differences 
in  exposure  to  Mycobacterium  tuberculosis  [43-46].  Con-
ventional DMARDs and corticosteroids are also associated 
with an increased risk of tuberculosis [47]. 
  A Swedish study over the period 2000-2001 reported a 4-
fold increase in TB risk for RA patients treated with TNF 
antagonists [48], whereas a Korean study observed a relative 
risk of TB of 8.9 for RA patients and 30.1 for RA patients 
treated  with  infliximab  in  comparison  with  the  general 
population  [49].  In  the  Spanish  biologicals  register 
BIOBADASER,  annual  TB  incidence  rates  of  1893  and 
1113 per 100 000 were reported in the year 2000 and 2001 
respectively, in anti-TNF treated RA patients, in comparison 
with  95/100  000  in  RA  patients  not  treated  with  TNF 
inhibitors and 20/100 000 in the general population [50,51]. 
  Reactivation of latent tuberculosis emerged as an adverse 
event from early clinical experience with the first generation 
TNF antagonists (reviewed in [52,53]), concurrent with the 
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bacteria [54,55]: TNF stimulates phagocytosis of mycobac-
teria by macrophages and enhances mycobacterial killing in 
concert with IFN-γ, is crucial in recruitment of inflammatory 
cells  and  stimulates  chemokine  production  [59,60].  TNF 
further  plays  a  key  role  in  confining  mycobacteria  to 
granulomas and achieving a latent state of the disease, which 
may explain both the timing of disease reactivation,usually 
observed  within  the  first  months  of  treatment,  and  the 
difference  between  the  different  TNF  antagonist,  which 
display different kinetics leading to different TNF bioavaila-
bility in granulomatous tissue [56,57]. 
  Later trials with newer biologicals have used TB screen-
ing and prophylaxis or excluded patients with evidence of 
previous TB exposure and hence reported much lower TB 
incidence rates. The impact and importance of TB screening 
and prophylaxis is further illustrated by the drastic decrease 
in  TB  cases  after  implementation  of  TB  screening  and 
prophylaxis guidelines [50,58]. The majority of TB cases in 
anti-TNF  treated patients  afterwards were due  to incorrect 
implementation of TB screening and prophylaxis guidelines 
[42,50]. TB risk with the anti-TNF antibodies infliximab and 
adalimumab is higher than with the fusion protein etanercept 
[42]. A recent study presenting long-term follow-up data on 
patients with TB as a complication of TNF blocker therapy 
shows  that  biological  therapy  can  be  safely  resumed  after 
adequate treatment of TB [41]. 
  The tuberculosis risk associated with rituximab is curren-
tly  unknown.  No  tuberculosis  was  reported  in  rituximab 
RCTs  [26-28].  The  consensus  statement  on  the  use  of 
biologicals in RA warns against the use of rituximab in the 
presence of serious or opportunistic infections [59], but some 
case reports described the use of rituximab without adverse 
consequences in patients with a history of active TB [60,61].  
  The  risk  for  TB  reactivation  associated  with  abatacept 
therapy  currently  remains  unknown,  but  one  case  of 
tuberculosis has been observed in phase III trials with this 
drug  [32].  Although  the  B7/CD28  T  cell  costimulation 
pathway  plays  a  role  in  the  granulomatous  response  to 
mycobacterium infection [62], abatacept did not exacerbate 
mycobacterium  tuberculosis  infection  in  mice,  in  contrast 
with  anti-TNF  treatment  [63].  The  clinical  significance  of 
these  experimental  findings  remains  to  be  investigated, 
however. Therefore, TB screening prior to abatacept therapy 
is recommended until the TB reactivation risk is known [59].  
  For  the  recently  introduced  IL-6  receptor  antagonist 
tocilizumab the risk of tuberculosis reactivation appears to 
be low. No cases of tuberculosis reactivation under tocilizu-
mab treatment were reported up to now [40,64-69], despite 
the  fact  that  most  clinical  trials  with  tocilizumab  did  not 
perform  tuberculosis  screening  or  prophylaxis  and  tuber-
culosis was an exclusion criterion in only two trials [68,69]. 
In view of the well-established role of IFN-γ production in 
the antituberculosis immune response [70], in vitro findings 
that tocilizumab, in contrast with infliximab and etanercept, 
does not impair IFN-γ production in response to mycobac-
terial  antigen  exposure  [71],  and  Mycobacterium  tubercu-
losis-induced  interleukin  6  inhibits  the  responsiveness  of 
macrophages towards IFN-γ [72], may suggest a low risk for 
TB  reactivation  during  tocilizumab  therapy.  The  clinical 
significance  of  these  experimental  findings  remains  to  be 
investigated,  however.  As  available  clinical  data  on 
tuberculosis risk under tocilizumab treatment are too limited 
to estimate the TB risk for this compound, screening for TB 
according  to  local  practice  before  initiating  tocilizumab 
therapy is recommended [59]. 
  In  addition  to  the  risk  of  TB  reactivation,  biological 
therapy  is  also  believed  to  increase  the  risk  of  nontuber-
culous or atypical mycobacterial infections, including M. 
avium complex, M. chelonae, M. marinum and M. abscessus. 
Nontuberculous  mycobacteria  are  ubiquitously  found  in 
water and soil and known to cause lung infections in patients 
with underlying lung disease, skin and soft tissue infections 
and disseminated disease in severely immunocompromised 
patients  [73].  Published  data  on  atypical  mycobacterial 
infections under biological therapy are scarce, with the FDA 
surveillance  system  reporting  an  incidence  lower  than  TB 
under  anti-TNF  therapy  [74,75],  whereas  the  Emerging 
Infections  Network  of  the  Infectious  Disease  Society  of 
America  suggested  a  higher  incidence  than  that  of  TB  in 
patients receiving TNF inhibitors. A possible explanation for 
this difference may be that TB incidence is declining due to 
screening and prophylaxis for TB, which has no effect on 
atypical mycobacteriosis [73]. Most cases of nontuberculous 
mycobacteriosis  were  observed  in  patients  treated  with 
infliximab and more than half of the cases presented with 
pulmonary disease [73].  
  Tubach et  al. reported  a series of pneumonia cases by 
infection  with  the  intracellular  bacteria  Legionella 
pneumophila in patients treated with TNF inhibitors. 5 out 
of 11 cases developed acute respiratory distress syndrome, 
but  all  recovered  with  appropriate  antibiotic  therapy.  The 
relative  risk  of  legionella  infection  in  RA  patients  treated 
with anti-TNF compounds was calculated to be between 16.5 
to 21.0 in comparison with the overall risk in France [76]. 
  Cases  of  infection  with  the  gram-positive  intracellular 
pathogen Listeria monocytogenes have been reported for all 
three first generation TNF antagonists [77-79]. Listeriosis in 
patients  treated  with  TNF  inhibitors  can  present  as  septic 
arthritis  [77,80,81],  meningitis  [82,83]  or  sepsis  [79,84]. 
Slifman et al. report 15 cases of Listeria infection associated 
with  anti-TNF  treatment  in  the  FDA  postmarketing 
surveillance system, 6 of them fatal, mainly in association 
with infliximab treatment (14/15 cases). They estimated the 
US  annual  incidence  of  Listeria  infection  to  be  43  per 
million in anti-TNF treated patients, versus 13 per million in 
the  general  population  aged  over  60  [85].  Experimental 
evidence indicates that TNF signaling plays a central role in 
the complex host resistance to listeria infection [86,87]. To 
date  there  are  no  reports  linking  the  newer  biologicals 
golimumab, certolizumab or abatacept with listeria infection. 
A  single  case  reports  describes  listeriosis  and  hepatitis  B 
reactivation in a leukemia patient treated with chemotherapy 
and rituximab [88].  
  In  view  of  the  serious  course  of  listeria  infections  in 
immunocompromised patients, Slifman recommends physi-
cians to advise patients receiving immunosuppressant ther-
apy, including anti-TNF compounds, to avoid or adequately 
heat  foods  that  are  potential  sources  of  L.  monocytogenes 
[85]. Visceral leishmaniasis represents a rare complication 
of  biological  treatments,  which  should  be  suspected  in 
patients  with  fluctuant  fever,  pancytopenia  and  spleno-
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Salmonella Infection 
  A  number  of  case  reports  indicate  that  treatment  with 
TNF inhibitors may  lead to  an increased susceptibility for 
infection  with  different  salmonella  species  [89-91].  A 
Spanish  cohort  study  found  the  risk  of  non-typhi  salmo-
nellosis in RA patients treated with biologicals at 0.73/1000 
patient-years not significantly increased in comparison with 
either  RA  patients  not  treated  with  biologicals  or  controls 
from the same region  without  RA. However,  the fact  that 
9/17 reported cases of salmonella infection in patients under 
biological  therapy  had  severe  systemic  infection,  suggests 
that biological therapy may predispose RA patients to a more 
serious  course  of  disease  in  case  of  Salmonella  infection 
[92].  
Viral Infections 
  The  immunosuppressive  effects  of  biological  therapies 
have also been associated with increased risk for reactivation 
of chronic viral infections, such as hepatitis B and C, herpes 
zoster and even PML.  
  TNF-α plays an important role in the host antiviral res-
ponse, so anti-TNF treatments may theoretically increase the 
reactivation risk of chronic viral infections. Polymorphisms 
in the TNF-α promoter, leading to inadequate TNF secretion, 
have  been  shown  to  adversely  influence  the  outcome  of 
hepatitis  B  infection  [93].  Moreover,  imbalance  between 
TNF-α  and  IFN-γ  impairs  viral  clearance  and  promotes 
evolution towards chronic infection [93,94]. A recent meta-
analysis  reported  no  such  association  of  TNF  gene 
polymorphisms and the susceptibility to hepatitis C infection 
[95], although TNF production was shown to be activated in 
hepatitis C infection [96]. 
  In  spite  of  the  intrinsic  underlying  risk  of  hepatitis 
reactivation,  biological  agents  represent  an  attractive  ther-
apeutic  answer  to the therapeutic  challenges posed by  RA 
patients with concurrent hepatitis, in view of the well-known 
hepatotoxic  side  effects  of  a  number  of  conventional 
DMARDs, such as MTX and leflunomide. 
  A  number  of  case  reports  alerted  clinicians  to  the 
potential  danger  of  reactivation  of  hepatitis B  under  anti-
TNF  therapy,  with  sometimes  serious  consequences,  like 
death  or  liver  transplantation  [97-99].  Available  data  on 
reactivation  of  hepatitis  B  under  anti-TNF  therapy  mainly 
come  from  case  reports  and  retrospective  studies  with  a 
limited  number  of  patients [99].  Chung  et  al.  reported 
hepatitis B reactivation in 1 out of 8 HBsAg carriers with 
normal  liver  function  and  undetectable  viral  load  [100]. 
Roux et al. found no increase in viral load in 3 patients with 
chronic  antiHBc  positive  hepatitis  B  concurrently  treated 
with  anti-TNF  and  lamivudine  [101].  None  of  the  three 
patients  with  hepatitis  B  (treated  with  etanercept  or 
adalimumab without antiviral prophylaxis) in the case series 
of  Li  et  al.  experienced  rises  in  serum  transaminases  or 
hepatitis B viral load [102]. Kaur et al. reported no negative 
effects  on  liver  histology  after  4  months  of  adalimumab 
therapy in a patient with a transient rise in hepatitis viral load 
[103]. Hepatic side effects and reactivation of viral hepatitis 
have been more frequently reported for infliximab than for 
either  adalimumab  or  etanercept.  This  may  be  due  to  the 
structural differences between these compounds [99].  
  Reactivation of viral hepatitis B has also been described 
in association with B cell depletion by rituximab treatment, 
mainly in an oncological setting [88,104].  
  Information on tocilizumab and hepatitis is limited to a 
case  report  describing  long-term  (6.5  years)  tocilizumab 
therapy without adverse consequences in a patient who was 
later discovered to be a hepatitis B carrier [105]. The effect 
of  inhibition  of  IL-6  signalling  on  the  course  of  viral 
hepatitis  remains  to  be  elucidated,  since  IL-6  has  been 
implicated in both hepatitis B related hepatocellular injury, 
as well as in hepatitis B viral clearance [105].  
  The  risk  of  hepatitis  reactivation  of  the  newer  TNF 
inhibitors,  golimumab  and  certolizumab  pegol,  are  still 
unknown,  as  is  the  hepatitis  B  risk  under  abatacept 
treatment. 
  Hepatitis  C  reactivation  under  biological  therapy  has 
been  described.    Several  retrospective  studies  reported  no 
hepatitis  C reactivation in a series of patients treated with 
infliximab  or  etanercept  [106-110].  Li  reports  one  patient 
with an increased viral load after switching from etanercept 
to  infliximab  [102],  whereas  the  study  of  Cansu  et  al. 
describes  reactivation  in  2  out  of  4  patients  [111].  In  a 
prospective study with 31 patients, one patient experienced 
drastic increase in ALT, 4 showed an increase in viral load 
and 19 patients were still on TNF therapy with good clinical 
response and stable liver enzymes and viral load after 22±11 
months of follow-up [112]. 
  Marotte  reported  a  good  safety  profile  of  3-months  of 
treatment with etanercept in RA patients with concomitant 
hepatitis  C  [113].  Beneficial  effects  of  etanercept  in  RA 
patients treated for hepatitis C with ribavirin and interferon 
alpha have also been reported [114,115].  
  Stable  liver  enzymes  and  hepatitis  viral  load  were 
reported for a treatment regimen consisting of anti-TNF ther-
apy in combination with cyclosporine A [116,117]. Besides 
its  well-known  immunosuppressive  effects,  cyclosporine 
also inhibits replication of the hepatitis virus [118,119] and 
may  therefore  be  a  good  choice  for  patients  with  chronic 
hepatitis C infection. 
  Herpes zoster is a neurocutaneous disease resulting from 
reactivation of the varicella zoster virus and is characterized 
by  a  painful  dermatomal  rash.  Complications  of  herpes 
zoster include bacterial superinfection and more importantly 
postherpetic  neuralgia,  which  can  cause  prolonged  and 
substantial morbidity. A condition of reduced cellular immu-
nity  increases  the  risk  of  developing  an  herpes  zoster 
episode.  Herpes  zoster  is  one  of  the  more  commonly 
occurring  infectious  complications  reported  in  RCTs  of 
biological agents for the treatment of RA [65-67,120], but 
this fact must be evaluated taking into account the increased 
incidence of herpes zoster in RA patients in comparison with 
the general population. Odds ratios for herpes zoster in RA 
patients treated with biologicals in a US health plan database 
population were modestly increased (OR 1.52, 95% CI 1.03-
2.23),  whereas  combination  of  biologicals  with  cortico-
steroids (OR 2.51, 95% CI 2.11-3.00) or triple therapy with 
biologicals, steroids and conventional DMARDs (OR 1.96, 
95% CI 1.02-3.80) yielded much higher herpes zoster risks 
[121]. A German RA registry study reported herpes zoster 
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years for the monoclonal anti-TNF antibodies infliximab and 
adalimumab, and 8.9 (95% CI, 5.6-13.3) for etanercept, in 
comparison  with  5.6  (95%  CI,  3.6-8.3)  for  conventional 
DMARDs  [120].  Studies  investigating  the  differences  in 
herpes zoster risk among the different TNF inhibitors yield 
conflicting results [120,122,123].  
  In patients under biological therapy, herpes zoster may 
present with atypical [124] or disseminated symptomatology 
[125,126]. 
  In view of their immunosuppressive effects,  the use of 
biologicals in  HIV positive patients remains controversial. 
Although  the  role  of  TNF  in  HIV  infection  is  not  fully 
elucidated yet, it appears to contribute to HIV pathogenesis 
rather than to its defense [127]. A number of reports indicate 
that TNF inhibitors can safely be used for HIV positive RA 
patients refractory to conventional therapies [127,128]. One 
of eight HAART-treated patients with stable CD4 counts in 
the  case  series  of  Cepeda  et  al.  experienced  an  infectious 
episode  under  anti-TNF  treatment  [128].  In  a  case  of  a 
psoriasis HIV-patient with low CD4 counts, etanercept treat-
ment  was  stopped  due  to  severe  polymicrobial  infec-
tion [129]. No studies on the use of other biologicals in HIV 
positive RA patients are available up to now. 
  Progressive multifocal  leukoencephalopathy or PML 
is  a  rare,  progressive,  usually  fatal  demyelinating  brain 
disease, caused by reactivation of latent JC virus, a polyoma 
virus. Although most cases of PML occur in settings with 
severe immunosuppression, such as AIDS, malignancies or 
overly immunosuppressed transplant patients, the disease has 
occasionally been described in rheumatic diseases, mostly in 
systemic lupus erythematosus [130]. Recently, an increasing 
number of PML cases in association with biological therapy 
with  antibodies  targeting  immune  mediators  have  been 
described [131,132]. Of relevance to RA, cases of PML have 
been  described  after  treatment  with  rituximab  [130,131, 
133,134] and recently also with tocilizumab [135].  
  PML  is  a  rare  complication  with  an  infaust  prognosis. 
Since  the  diagnosis  of  PML  is  difficult  and  the  most 
important  therapeutic  measure  consists  of  relieving  the 
immunosuppressed state, it is important for clinicians to be 
aware of its existence. 
PRECAUTIONS AND SCREENING BEFORE SELEC-
TING AND STARTING BIOLOGICAL THERAPY 
Screening and Prophylaxis for Latent Tuberculosis 
  In view of the risk of TB reactivation under biological 
therapy, it is advisable to assess a patient’s TB history and 
exposure.  Screening  for  latent  TB  is  recommended  for  all 
biological agents, except rituximab, where clinical vigilance 
would suffice in view of the paucity of arguments pointing 
towards an elevated tuberculosis risk with this drug [59].  
  Latent tuberculosis is sometimes operationally defined as 
the combination of absence of TB signs or symptoms in the 
presence of one or more risk factors for TB (TB exposure or 
underlying disease), together with a positive PPD (purified 
protein derivative) skin test [58]. 
  However, direct diagnosis of latent tuberculosis infection 
is not possible. The diagnostic tests used to identify indivi-
duals  latently  infected  with  M.  tuberculosis,  the  in  vivo 
tuberculin skin test and the ex vivo interferon-release assays 
(IGRAs),  are  designed  to  identify  an  adaptive  immune 
response against the bacterium, and do not directly diagnose 
the  presence  of  latent  mycobacteria.  Furthermore,  it  is 
currently unknown what the proportion of individuals with 
positive TB screening tests is that truly remains infected with 
mycobacteria or whether and how long the adaptive immune 
responses responsible for a positive test persist [136].  
  The tuberculin skin test is the classic in vivo TB screen-
ing test in which tuberculin PPD is injected intradermally. In 
the  presence  of  a  TB  immune  response,  PPD  injection  is 
followed by appearance of an induration at the injection site. 
The diameter of the induration considered positive depends 
upon the underlying risk status of the patient. In TB screen-
ing  of  RA  patients  before  the  start  of  biological  therapy 
indurations above 5 mm are usually considered positive. In 
the  follow-up  of  patients  under  biological  therapy  an  inc-
rease  in  induration  diameter  by  6mm  or  more  would  be 
indicative of TB reactivation [137]. Tuberculin skin testing 
is not very reliable in immunocompromised populations. The 
PPD  response  was  shown  to  be  subdued  in  RA  patients 
[138],  and  influenced  by  previous  BCG  vaccination 
[136,139].  
  The tuberculosis-specific interferon-gamma release assay 
(IGRA) as an alternative screening for latent TB has been 
adopted so eagerly by the clinical community, as to interfere 
with  the proper investigation of its predictive value [136]. 
Although  a  number  of  studies  report  better  results  in  RA 
patients  with  IGRA  in  comparison  with  tuberculin  skin 
testing  [140]  and  good  agreement  between  results  of 
different IGRAs [141], IGRA testing suffers from a certain 
percentage  of  indeterminate  results,  necessitating  the 
combination of both screening tests [142-145].  
  Patients  with  a  positive  TB  screening  test  should  be 
assessed for active disease with a  chest X-ray and  treated 
with  appropriate  prophylactic  TB  therapy.  Chemopro-
phylaxis  for  latent  TB  usually  consists  of  isoniazid  single 
therapy  for  9  months,  or  alternatively,  rifampicin  for  4 
months [58].  In  regions  with  TB  drug  resistance  of  >10% 
combination drug therapy must be considered. Liver function 
tests should be monitored every two to four weeks during TB 
treatment,  especially  in  patients  concurrently  taking 
potentially hepatotoxic medications [146].  
  A Greek retrospective study observed 11 cases of active 
TB  among  45/613  patients  fulfilling  the  criteria  for  TB 
chemoprophylaxis, with 3 cases occurring in a subset of 9 
patients not complying with the chemoprophylaxis scheme 
used. However, failure of TB prophylaxis in 8/36 compliant 
patients indicates that the TB prophylaxis schemes used in 
this study (6 months of isoniazid or isoniazid in combination 
with rifampicin for 3 months) were inadequate [147]. 
  In view of the evidence pointing towards a lower risk for 
tuberculosis reactivation with etanercept in comparison with 
infliximab  and  adalimumab  [42,148]  one  might  at  this 
moment consider etanercept as the  treatment of choice for 
patients with elevated TB risk (increased TB exposure due to 
socioeconomic  factors,  proven  contact  with  a  TB  case, 
positive tuberculin skin test), in combination with adequate 
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hand presently does not allow turning  this cautious consi-
deration into a true recommendation, in line with the recently 
published EULAR recommendations which do not mention 
any preference of one drug over another, nor take infection 
risk  into  consideration  in  any  of  the  15  recommendations 
[149].  
Hepatitis B and C Screening and Antiviral Prophylaxis 
  A screening and prophylaxis workup for hepatitis  B in 
RA patients has been described by Calabrese et  al. [150]. 
Prior to initiation of biological therapy hepatitis B serology 
should be assessed by HBsAg, anti-HBs and anti-HBc tests. 
Negative  patients  should  be  considered  for  hepatitis  B 
vaccination. Patients positive for hepatitis B core antibodies 
have gone through active hepatitis infection and should be 
monitored  closely  for  reactivation.  Addition  of  antiviral 
prophylaxis  should  be  considered  on  an  individual  patient 
basis. Periodical follow-up of liver enzymes and hepatitis B 
viral load is advised when no prophylaxis is given. Patients 
with  HBsAg  positivity  should  receive  prophylaxis  with 
antiviral drugs before starting immunosuppressive  therapy. 
Antiviral  prophylaxis  with  lamivudine  (100  mg/day)  has 
been used with good short-term results, while its long-term 
use may be involved in the development of resistant HBV 
strains. Little information is available on alternative antiviral 
therapies in RA [150]. 
  Screening for hepatitis C virus prior to biological therapy 
is appropriate [127]. In view of the role of TNF in hepatitis 
C  infection  and  the  relative  safety  of  TNF  blockers  in 
patients  with  hepatitis  C  infection,  no  change  of  antiviral 
therapy is needed, provided there is adequate monitoring of 
liver enzymes and viral load [112]. 
HIV 
  HIV  screening  prior  to  biological  therapy  is  recom-
mended  in  patients  with  risk  behavior.  Biological  therapy 
should  be  reserved  for  stable  HIV  positive  patients  with 
adequate (>200/ml) CD4 cell counts [127]. 
Vaccination 
  RA  patients  treated  with  biological  therapy  must  be 
regarded  as  immunocompromised  individuals  and  are  as 
such  at  increased  risk  of  infection  and  complications  for 
some  vaccine-preventable  diseases.  The  benefits  of  vacci-
nation in this population are even greater than in the general 
population,  but  vaccination  coverage  is  surprisingly  low 
[151,152]. 
  Like in all immunocompromised individuals, live vacci-
nes  (measles-mumps-rubella,  varicella  and  zoster  vaccine, 
yellow fever, oral poliomyelitis) are contraindicated in RA 
patients under biological therapy. For inactivated vaccines, 
biological therapy may have a negative impact on the quality 
of the vaccine-induced immune response. Therefore, vacci-
nation status should be checked and updated as appropriate 
before the start of biological therapy.  
  Live vaccines need to be given 3 to 4 weeks prior to the 
start  of  therapy  to  ensure  clearance  of  the  vaccine  virus 
before the immune response is impaired. The waiting period 
needed  before  administering  live  vaccines  after  biological 
therapy  discontinuation  depends  on  the  type,  dose  and 
duration of the therapy [153]. As a rule of thumb, a period of 
3 months is estimated to be sufficient for restoration of the 
immune  response.  For  rituximab,  B  cell  repletion  and 
adequate restoration of the immune response may require a 
longer period of 6 to 10 months [154]. 
  Inactivated  vaccines  can  be  safely  administered  during 
biological  therapy.  Although  the  influenza,  pneumococcal 
and hepatitis B vaccines have been demonstrated to be safe 
and  effective  in  RA  patients  treated  with  biologicals,  a 
number of studies indicate  that  the quality of the vaccine-
elicited  immune  response  in  these  patients  is  lower,  with 
either  reduced  seroconversion  rates  after  vaccination  – 
leaving a subset of patients unprotected - or reduced quantity 
or quality of the antibody response to the vaccine, which in 
turn  may  have  a  negative  effect  on  the  duration  of 
protection [155]. 
CONCLUSIONS 
  Clinicians considering starting biological therapy for an 
RA patient should be aware that biological therapy further 
increases the already moderately increased infection risk of 
the RA patient. Precautions needed before the start of bio-
logical therapy include checking and updating the patient’s 
vaccination status and screening for latent tuberculosis. 
  Current  evidence  includes  insufficient  data  from  com-
parative  studies  to  make  recommendations  concerning  the 
choice  of  biological  from  an  infection  risk  perspective. 
However,  the  lower  risk  for  tuberculosis  reactivation 
reported  for  etanercept  in  comparison  with  infliximab  and 
adalimumab  may  cautiously  prompt  the  consideration  of 
etanercept as the product of choice for patients with elevated 
TB risk.  
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